SCHEMBL7521202

SCHEMBL7521202

O=C1NC(=O)/C(=C\c2ccc(-c3nc4cc(Cl)c(Cl)cc4n3Cc3ccc4ccccc4n3)cc2)S1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 4/20 0.63
GAA P10253 4/20 0.63
SI P14410 4/20 0.63
MGAM2 Q2M2H8 4/20 0.63
GSK3B P49841 1/20 0.47
IGF1R P08069 1/20 0.43
KCNH2 Q12809 1/20 0.41
PIM1 P11309 4/20 0.41
PIM2 Q9P1W9 3/20 0.40
HPGD P15428 2/20 0.40
PARP1 P09874 2/20 0.40
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
PIM3 Q86V86 1/20 0.40
GLS O94925 1/20 0.39
GLS2 Q9UI32 1/20 0.39
PPARG P37231 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
CISD1 Q9NZ45 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7521205 1.00 MGAM (0.63) MGAMGAASIMGAM2GSK3B
SCHEMBL7515222 0.87 MGAM (0.72) MGAMGAASIMGAM2IGF1R
SCHEMBL7515220 0.87 MGAM (0.72) MGAMGAASIMGAM2IGF1R
SCHEMBL7525388 0.86 MGAM (0.69) MGAMGAASIMGAM2GSK3B
SCHEMBL7525385 0.86 MGAM (0.69) MGAMGAASIMGAM2GSK3B
SCHEMBL7516898 0.84 RHEB (0.43) MGAMGAASIMGAM2KCNH2
SCHEMBL7519414 0.83 MGAM (0.57) MGAMGAASIMGAM2IGF1R
SCHEMBL7519419 0.83 MGAM (0.57) MGAMGAASIMGAM2IGF1R
SCHEMBL7514347 0.82 MGAM (0.68) MGAMGAASIMGAM2IGF1R
SCHEMBL7514352 0.82 MGAM (0.68) MGAMGAASIMGAM2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 MGAM 3441/4885GAA 625/4885SI 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.